|Synonyms||5-[2-Ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4H-pyrazolo[5,4-e]pyrimidin-7-one citrate salt; Actra-Rx; Edegra; Viagra; Tonafil; Apodefil; UK 92480|
|Formula||C22H30N6O4S . C6H8O7|
|MW||474.6 . 192.1|
|Purity Chemicals||≥98% (HPLC)|
|Appearance||White to off-white powder.|
|Solubility||Soluble in DMSO (20mg/ml).|
|Identity||Determined by NMR.|
|Declaration||Manufactured by Chemodex.|
|Other Product Data||
Click here for Original Manufacturer Product Datasheet
|Shipping and Handling|
|Short Term Storage||+20°C|
|Long Term Storage||+4°C|
Keep cool and dry.
Protect from light and moisture.
|Use/Stability||Stable for at least 2 years after receipt when stored at +4°C.|
|Product Specification Sheet|
Potent cGMP-specific phosphodiesterase inhibitor that is highly selective for PDE5. It inhibits PDE5 activity in isolated rabbit platelets with an IC50 value of 3.6nM (3nM in human corpus cavernosum) compared to inhibition of PDE1 and PDE3 activities (IC50s = 0.26 and 65μM, respectively). Inhibition of PDE5 enhances the relaxation of smooth muscle in a range of vascular tissues by prolonging the nitric oxide/cGMP-mediated activation of cGMP-dependent protein kinase. While most notable for its use in the treatment of erectile dysfunction, sildenafil’s vasorelaxant properties have also been used to control vascular tone in pulmonary arterial hypertension and high-altitude pulmonary edema associated with altitude sickness. The citrate salt has superior water solubility and pharmacokinetics compared to the base salt of sildenafil.
(1) N.K. Terrett, et al.; Bioorg. Med. Chem. Lett. 6, 1819 (1996) | (2) J. Richalet, et al.; Am. J. Respir. Crit. Care Med. 171, 275 (2005) | (3) C.E. Teixeira, et al.; J. Pharmacol. Exp. Ther. 316, 654 (2006) | (4) S. Jung, et al.; Arch. Pharm. Res. 34, 451 (2011)